Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin

• Main Authors: Andrea A. Berry (Author), Remon Abu-Elyazeed (Author), Clemente Diaz-Perez (Author), Maurice A. Mufson (Author), Christopher J. Harrison (Author), Michael Leonardi (Author), Jerry D. Twiggs (Author), Christopher Peltier (Author), Stanley Grogg (Author), Antonio Carbayo (Author), Steven Shapiro (Author), Michael Povey (Author), Carmen Baccarini (Author), Bruce L. Innis (Author), Ouzama Henry (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

One combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R...